oyalty Pharma reports third quarter 2026 results
Portfolio Receipts growth of9%to$890 million; RoyaltyReceipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million
— Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra. Lastly, we remain excited by the potential for R&D co-funding with global biopharma - where we have announced $1 billion of transactions so far this year - which represents an important new opportunity for our business. Looking ahead, with a robust deal pipeline and strong fundamental tailwinds supporting our business, we remain well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”
• Royalty Receipts grew 9% to $883 million, driven by Tremfya, Voranigo, Evrysdi and Imdelltra.
• Portfolio Receipts increased by 9% to $890 million, reflecting higher milestones and other contractual receipts.
• Acquired a royalty on Arcutis Biotherapeutics’ Zoryve for $100 million and on Takeda’s Mimrylo for $100 million.
• Announced value of transactions of $1.9 billion and Capital Deployment of $1.6 billion as of November 3, 2026.
• FDA approvals for Revolution Medicines’ Rasonque (daraxonrasib) for metastatic pancreatic cancer, Teva’s Weltruza (olanzapine LAI) for schizophrenia and Jazz and BeOne’s Ziihera for HER2+ metastatic gastric cancer.
• Positive Phase 3 results for Amgen’s Imdelltra as a first-line maintenance therapy for small cell lung cancer and Pharvaris’ deucrictibant XR for prophylaxis of hereditary angioedema attacks.
Raising financial guidance for full year 2026 (excludes contribution from future transactions)
• Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500 million and $3,550 million (previously $3,400 million to $3,500 million), representing expected Royalty Receipts growth of 10% to 11%.
Three Months Ended September 30, ($ and shares in millions; 2026 2025 Change unaudited) Portfolio Receipts 890 814 9% Net cash provided by operating 686 703 (2)% activities Adjusted EBITDA (non-GAAP)* 840 779 8% Portfolio Cash Flow 673 657 2% (non-GAAP)* Weighted average Class A ordinary shares 557 560 (0)% outstanding - diluted
*See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.
Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows:
Provided November 4, 2026 Previous ────────────────────────────────────────────────────────────────────────────── Portfolio Receipts $3,500 million to $3,400 million to $3,550 million $3,500 million Payments for operating 5.5% to 6.0% of 5.5% to 6.5% of and professional Portfolio Receipts Portfolio Receipts costs Interest paid $350 million to $360 $350 million to $360 million million
Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. The above Portfolio Receipts guidance provided on November 4, 2026 includes expected Royalty Receipts growth of 10% to 11% in 2026.
Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange impact of approximately +1% to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2026.
Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due to extinguishment of the management fee following the completion of the internalization transaction on May 16, 2025.
Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and the quarterly interest payment schedules for the term loan assumed as part of the internalization transaction and borrowings under our revolving credit facility. In 2026, Royalty Pharma anticipates interest paid to be approximately $350 million to $360 million. Interest paid is anticipated to be a de minimis amount in the fourth quarter of 2026. These projections assume no additional debt financing in 2026. In the third quarter of 2026, Royalty Pharma collected interest of $6 million on its cash and cash equivalents, which partially offset interest paid.
Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.
Three Months Ended September 30, ($ in millions; 2026 2025 Change unaudited) Products: Marketers: Therapeutic Area: Cystic Rare fibrosis Vertex disease 225 222 1% franchise Trelegy GSK Respiratory 89 96 (6)% Tremfya Johnson & Immunology 80 49 61% Johnson Evrysdi Roche Rare 71 52 38% disease Tysabri Biogen Neuroscien… 67 68 (1)% Voranigo Servier Oncology 55 33 65% Xtandi Pfizer, Oncology 51 50 3% Astellas AbbVie, Imbruvica Johnson & Oncology 31 41 (24)% Johnson Exelixis, Cabometyx/… Ipsen, Oncology 24 21 13% Takeda Imdelltra Amgen Oncology 19 — n/a Trodelvy Gilead Oncology 16 12 30% Spinraza Biogen Rare 14 14 0% disease Amvuttra Alnylam Rare 10 — n/a disease Promacta Novartis Hematology 9 38 (75)% Other 121 114 6% products(5) Royalty 883 811 9% Receipts Milestones and other 7 3 138% contractual receipts Portfolio 890 814 9% Receipts
was $883 million in the third quarter of 2026, an increase of 9% compared to $811 million in the third quarter of 2025. The increase was primarily driven by Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by declines from Promacta due to U.S. generic competition and from Imbruvica. Royalty Receipts from Evrysdi included the benefit of the additional royalties acquired in December 2025.
was $890 million in the third quarter of 2026, an increase of 9% compared to $814 million in the third quarter of 2025, primarily driven by the same Royalty Receipts increases noted above, in addition to higher Milestones and other contractual receipts.
As of September 30, 2026, Royalty Pharma had cash and cash equivalents of $514 million and total debt with principal value of $8.8 billion. The reduction in total debt from $9.2 billion as of June 30, 2026 reflects payment of the $380 million term loan in July 2026.
In the third quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235 per share, equating to $135 million in dividends and distributions.
Royalty Pharma repurchased approximately 1.5 million Class A ordinary shares for $87 million in the third quarter and 3.5 million Class A ordinary shares for $183 million during the first nine months of 2026. The weighted-average number of diluted Class A ordinary shares outstanding for the third quarter of 2026 was 557 million as compared to 560 million for the third quarter of 2025.
Three Months Ended September 30, ($ in millions; unaudited) 2026 2025 Portfolio Receipts 890 814 Payments for operating and professional -50 -34 costs Adjusted EBITDA (non-GAAP) 840 779 Interest paid, net -167 -123 Portfolio Cash Flow (non-GAAP) 673 657
was $840 million in the third quarter of 2026. Payments for operating and professional costs were 5.6% of Portfolio Receipts. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs.
was $673 million in the third quarter of 2026. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.
Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.
Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $362 million in the third quarter of 2026, consisting primarily of R&D funding for JNJ‑4804 and upfront payments for cliramitug, Zoryve and Mimrylo (see 'Royalty Transactions'). Capital Deployment was $1.2 billion for the nine months ended September 30, 2026, with the announced value of transactions of $1.9 billion.
Three Months Nine Months Ended September Ended September 30, 30, ($ in millions; 2026 2025 2026 2025 unaudited) Purchases of available for — — — -75 sale debt securities Acquisitions of financial -279 -962 -982 -964 royalty assets Development-st… funding -70 -51 -193 -402 payments Milestone -13 — -63 -269 payments Contributions from legacy — -0 — 0 non-controlling interests - R&D Capital -362 -1,013 -1,239 -1,709 Deployment
As of November 3, 2026, Royalty Pharma has announced new transactions of up to $1.9 billion, which reflects the entire amount of potential capital committed for new transactions, including potential future milestones. In the third quarter of 2026, the following transactions were announced:
• In September 2026, Royalty Pharma acquired a royalty interest in Zoryve from AstraZeneca for $100 million upfront. Zoryve, marketed by Arcutis Biotherapeutics, is a topical phosphodiesterase type 4 (PDE4) inhibitor approved for atopic dermatitis, seborrheic dermatitis and plaque psoriasis.
• In August 2026, Royalty Pharma acquired a royalty interest in Mimrylo, formerly known as rusfertide, from Zealand Pharma for $100 million, consisting of $50 million paid upfront and the remaining $50 million payable on the first anniversary of the closing. Marketed by Takeda, Mimrylo is a first-in-class therapy approved for polycythemia vera, a rare and chronic blood disorder.
• In July 2026, Royalty Pharma acquired a portion of Neurimmune AG’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 first-in-class transthyretin (TTR)-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart.
The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com .
The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.
In October 2026, Novartis announced that the regulatory submission for pelabresib in pelabresib myelofibrosis was completed in the European Union, based on the positive Phase 3 MANIFEST-2 study. In October 2026, Revolution Medicines announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. In October 2026, Royalty Pharma funded the required first $250 million tranche of the up to $750 million senior secured term loans to Revolution Medicines. Additionally, Revolution Medicines elected not to exercise its option for Rasonque (daraxonrasib) the third royalty funding tranche (which was up to $250 million). Up to an additional $500 million may be available at Revolution Medicines’ option under each of the senior secured term loan and royalty funding agreement, based on the achievement of certain milestones. In August 2026, Revolution Medicines announced that the U.S. Food and Drug Administration (FDA) approved Rasonque for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. In October 2026, Syndax Pharmaceuticals (Syndax) announced that the Phase 2 MAXPIRe trial of Niktimvo in idiopathic pulmonary fibrosis (IPF) Niktimvo did not meet its primary endpoint. Syndax does not plan to move forward with further development in IPF. The results do not affect ongoing trials of Niktimvo in other indications. In October 2026, Teva Pharmaceuticals (Teva) announced that the FDA approved Weltruza for Weltruza (TEV-’749) extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. In September 2026, Roche announced that Phase 3 trontinemab studies of trontinemab in early Alzheimer’s disease have fully enrolled, with data expected in the first half of 2028. In September 2026, Amgen announced positive results from the Phase 3 DeLLphi-305 study of Imdelltra in combination with Imfinzi as first-line maintenance treatment for extensive-stage small cell lung cancer. The study Imdelltra met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival, and also met secondary endpoints of progression-free survival and objective response rate.
In September 2026, Pharvaris announced positive results from the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release for the prevention of hereditary angioedema (HAE) attacks. The primary endpoint and all secondary efficacy endpoints were met with statistical significance. In July 2026, Pharvaris announced that the FDA accepted its New Drug Application (NDA) for deucrictibant immediate-release for the on-demand treatment of HAE attacks and assigned a Prescription Drug User Fee Act (PDUFA) date of April 23, 2027. In September 2026, Novartis announced that the Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events in the overall study population compared to placebo. In the third quarter of 2026, Royalty Pharma recorded a non-cash deucrictibant impairment charge of $150 million pelacarsen related to pelacarsen. ────────────────────────────────────────────────────────────────────────────── In September 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-’408, an anti-IL-15 antibody, in adults with celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of TEV-’408 gluten-induced intestinal damage versus placebo at week 8, and was well tolerated, with no safety signals observed to date. In July 2026, Teva announced plans to advance TEV-’408 into a Phase 2b study in patients with non-segmental vitiligo, following positive Phase 1b results. In August 2026, Takeda announced that the FDA approved Mimrylo, a Mimrylo (rusfertide) hepcidin mimetic peptide, for the treatment of erythrocytosis in adults with polycythemia vera. In August 2026, Jazz Pharmaceuticals announced that the FDA approved Ziihera in combination with chemotherapy, with or without Ziihera tislelizumab, for the first-line treatment of adults with metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma. In August 2026, Gilead announced that the European Commission approved Trodelvy in combination Trodelvy with Keytruda as a first-line treatment for PD-L1-positive metastatic triple-negative breast cancer. In August 2026, Teva announced that the FDA accepted its NDA for ecopipam for the treatment of ecopipam pediatric Tourette syndrome and granted the application Priority Review with a PDUFA date late in the first quarter of 2027. In August 2026, Zenas BioPharma announced that the FDA accepted for review its Biologics License obexelimab Application for obexelimab for the treatment of immunoglobulin G4-related disease (IgG4-RD) and assigned a PDUFA target action date of May 27, 2027. In July 2026, GSK announced that the FDA approved Jideytro, a ROS proto-oncogene 1 (ROS1)-selective inhibitor, for the treatment of adult patients with metastatic ROS1-positive non-small cell lung cancer who have received a prior Jideytro (zidesamtinib) and ROS1 kinase inhibitor. neladalkib In July 2026, GSK announced that it completed the acquisition of Nuvalent for approximately $10.6 billion, including Jideytro and neladalkib, two highly selective ROS1 and anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Royalty Pharma will host a conference call and simultaneous webcast to discuss its third quarter of 2026 results today at 8:00 a.m. Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top- line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 16 development-stage product candidates.
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.
This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.
For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.
Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.
Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy. 2025 Portfolio Receipts does not include the $511 million of proceeds from the sale of the MorphoSys Development Funding Bonds, as the transaction was treated as an asset sale.
Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities a nd Distributions from equity method investees less Distributions to legacy non-controlling interests - Portfolio Receipts , which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.
Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.
The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.
Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.
The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.
Three Months Ended September 30, ($ in millions) 2026 2025 Income and other revenues Income from financial royalty 648 579 assets Other royalty income and 42 30 revenues Total income and other revenues 690 609 Operating (income)/expense Provision for changes in expected cash -88 12 flows from financial royalty assets Provision for credit losses on unfunded 4 1 commitments Research and development funding 63 51 expense General and administrative expenses (includes 105 and 73 of share-based compensation expense for the 150 119 three months ended September 30, 2026 and 2025, respectively) Financial royalty asset 150 — impairment Total operating expense, net 279 182 Operating income 411 427 Other (income)/expense Equity in earnings of equity method -9 -16 investees Interest expense 90 80 Other expense/(income), net 63 -77 Total other expense/(income), 144 -13 net Consolidated net income before 267 440 tax Income tax expense — — Consolidated net income 267 440 Net income attributable to 122 156 non-controlling interests Net income attributable to Royalty 145 284 Pharma plc
Three Months Nine Months Ended September Ended September 30, 30, ($ in millions) 2026 2025 2026 2025 Cash flows from operating activities: Cash collections from financial 930 882 2,660 2,439 royalty assets Cash collections from intangible 0 0 4 1 royalty assets Other royalty cash 38 29 104 85 collections Distributions from equity 8 — 33 13 method investees Interest 6 7 18 28 received Development-st… funding -70 -51 -193 -402 payments Payments for operating and -50 -34 -123 -230 professional costs Payments for -3 -2 -18 -2 Employee EPAs Interest paid -173 -130 -352 -270 Net cash provided by 686 703 2,133 1,663 operating activities Cash flows from investing activities: Acquisition of businesses, net — -0 — -74 of cash acquired Distributions from equity 1 1 30 100 method investees Purchases of equity — — -28 -4 securities Proceeds from equity — — 36 — securities Purchases of available for — — — -75 sale debt securities Proceeds from available for 6 3 14 18 sale debt securities Proceeds from sales of available for — — — 511 sale debt securities Acquisitions of financial -279 -962 -982 -964 royalty assets Milestone -13 — -63 -269 payments Other -0 — -1 -9 Net cash used in investing -286 -958 -993 -766 activities Cash flows from financing activities: Distributions to legacy non-controlling -93 -102 -257 -276 interests - Portfolio Receipts Distributions to continuing -33 -34 -108 -127 non-controlling interests Dividends to -105 -95 -315 -284 shareholders Repurchases of Class A -86 -146 -181 -1,147 ordinary shares Contributions from legacy — -0 — 0 non-controlling interests - R&D Contributions from non-controlling — 0 — 6 interests - other Proceeds from revolving 50 1,275 50 1,275 credit facility Repayment of revolving -50 -1,275 -50 -1,275 credit facility Repayment of -380 -1,000 -380 -1,000 long-term debt Proceeds from issuance of long-term — 1,954 — 1,954 debt, net of discount Debt issuance 0 -14 -2 -14 costs and other Other -1 — -2 — Net cash (used in)/provided by -699 563 -1,245 -886 financing activities Net change in cash and cash -298 307 -105 10 equivalents Cash and cash equivalents, 812 632 619 929 beginning of period Cash and cash equivalents, 514 939 514 939 end of period
Three Months Ended September 30, ($ in millions) 2026 2025 Net cash provided by operating 686 703 activities (GAAP) Adjustments: Proceeds from available for sale debt 6 3 securities(6) Distributions from equity method 1 1 investees(6) Interest paid, net(6) 167 123 Development-stage funding 70 51 payments Distributions to legacy non-controlling -93 -102 interests - Portfolio Receipts(6) Payments for Employee EPAs 3 2 Adjusted EBITDA (non-GAAP) 840 779 Interest paid, net(6) -167 -123 Portfolio Cash Flow (non-GAAP) 673 657
Cystic fibrosis franchise Cystic fibrosis Trelegy Chronic obstructive pulmonary disease and asthma Tremfya Plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease Evrysdi Spinal muscular atrophy Tysabri Relapsing forms of multiple sclerosis Voranigo Low-grade glioma Xtandi Prostate cancer Imbruvica Hematological malignancies and chronic graft versus host disease Cabometyx/Cometriq Kidney, liver and thyroid cancer Imdelltra Small cell lung cancer Trodelvy Breast cancer Spinraza Spinal muscular atrophy Amvuttra Transthyretin amyloidosis Promacta Chronic immune thrombocytopenia purpura and aplastic anemia
(1) Portfolio Receipts is defined above in the section entitled “Portfolio Receipts.”
(2) Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP condensed consolidated statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.
(3) Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.
(4) Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments and Development-stage funding payments less Contributions from legacy non-controlling interests - R&D .
(5) Other products primarily include Royalty Receipts on the following products: Crysvita, Erleada, Farxiga/Onglyza, IDHIFA, Niktimvo, Nurtec ODT, Orladeyo, Prevymis, Skytrofa, Yorvipath and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP condensed consolidated statements of cash flows.
(6) The table below shows the line item for each adjustment and the direct location for such line item on the GAAP condensed consolidated statements of cash flows.
Reconciling Adjustment Statements of Cash Flows Classification Interest paid, net Operating activities(Interest paidlessInterest received) Distributions from equity method Investing activities investees Proceeds from available for sale debt Investing activities securities Distributions to legacy non-controlling Financing activities interests - Portfolio Receipts
(7) The condensed consolidated statement of operations for 2025 has been recast to reflect the adoption of ASU 2025-07 by removing the gains previously recognized on derivative.
Full text with the tables
Press Release
November 4, 2026
──────────────────
R
oyalty Pharma reports third quarter 2026 results
Portfolio Receipts growth of9%to$890 million;
RoyaltyReceipts growth of 9%
Net cash provided by operating activities of $686
million
Raised full year 2026 guidance:
Portfolio Receipts expected to be $3,500 million
to $3,550 million
NEW YORK, NY, November 4, 2026
— Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the
third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.
“Royalty Pharma delivered excellent third quarter
2026 results and we again raised our financial
guidance,” said Pablo Legorreta, Royalty Pharma’s
Chief Executive Officer and Chairman of the Board.
“We delivered 9% growth in Royalty Receipts for
the quarter and double-digit growth year-to-date.
We continued to strengthen our portfolio by adding
royalties on three innovative therapies in the
third quarter. We have also seen tremendous
clinical and regulatory progress across our
portfolio, including FDA approvals of Revolution
Medicines’ Rasonque and Teva’s Weltruza and
positive Phase 3 results for Amgen’s Imdelltra.
Lastly, we remain excited by the potential for R&D
co-funding with global biopharma - where we have
announced $1 billion of transactions so far this
year - which represents an important new
opportunity for our business. Looking ahead, with
a robust deal pipeline and strong fundamental
tailwinds supporting our business, we remain well
positioned as a premier capital allocator in life
sciences to deliver consistent, compounding
growth.”
Strong growth in Royalty Receipts in the third quarter of 2026
• Royalty Receipts grew 9% to $883 million, driven by Tremfya, Voranigo, Evrysdi
and Imdelltra.
• Portfolio Receipts increased by 9% to $890 million, reflecting higher
milestones and other contractual receipts.
Continued healthy transaction activity
• Acquired a royalty on Arcutis Biotherapeutics’ Zoryve for $100 million and on
Takeda’s Mimrylo for $100 million.
• Announced value of transactions of $1.9 billion and Capital Deployment of $1.6
billion as of November 3, 2026.
Positive regulatory and clinical updates across royalty portfolio
• FDA approvals for Revolution Medicines’ Rasonque (daraxonrasib) for metastatic
pancreatic cancer, Teva’s Weltruza (olanzapine LAI) for schizophrenia and Jazz
and BeOne’s Ziihera for HER2+ metastatic gastric cancer.
• Positive Phase 3 results for Amgen’s Imdelltra as a first-line maintenance
therapy for small cell lung cancer and Pharvaris’ deucrictibant XR for
prophylaxis of hereditary angioedema attacks.
Raising financial guidance for full year 2026 (excludes contribution from future
transactions)
• Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500
million and $3,550 million (previously $3,400 million to $3,500 million),
representing expected Royalty Receipts growth of 10% to 11%.
Financial & Liquidity Summary
Three Months Ended
September 30,
($ and shares in millions; 2026 2025 Change
unaudited)
Portfolio Receipts 890 814 9%
Net cash provided by
operating 686 703 (2)%
activities
Adjusted EBITDA (non-GAAP)* 840 779 8%
Portfolio Cash Flow 673 657 2%
(non-GAAP)*
Weighted average Class A
ordinary shares 557 560 (0)%
outstanding - diluted
*See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio
Cash Flow are non-GAAP liquidity measures calculated in accordance with the
credit agreement.
Royalty Pharma Press Release| November 4, 2026 1
─────────────────────────────────────────────────────
2026 Financial Outlook
Royalty Pharma has provided guidance for full year 2026, excluding new
transactions and borrowings announced after the date of this release, as
follows:
Provided November 4,
2026 Previous
──────────────────────────────────────────────────────────────────────────────
Portfolio Receipts $3,500 million to $3,400 million to
$3,550 million $3,500 million
Payments for operating 5.5% to 6.0% of 5.5% to 6.5% of
and professional Portfolio Receipts Portfolio Receipts
costs
Interest paid $350 million to $360 $350 million to $360
million million
Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and
other contractual receipts. The above Portfolio Receipts guidance provided on
November 4, 2026 includes expected Royalty Receipts growth of 10% to 11% in
2026.
Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange
impact of approximately +1% to Portfolio Receipts, assuming current foreign
exchange rates prevail for the rest of 2026.
Payments for operating and professional costs in 2026 are expected to decrease
as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due
to extinguishment of the management fee following the completion of the
internalization transaction on May 16, 2025.
Total interest paid is based on the semi-annual interest payment schedule of
Royalty Pharma’s existing notes and the quarterly interest payment schedules for
the term loan assumed as part of the internalization transaction and borrowings
under our revolving credit facility. In 2026, Royalty Pharma anticipates
interest paid to be approximately $350 million to $360 million. Interest paid is
anticipated to be a de minimis amount in the fourth quarter of 2026. These
projections assume no additional debt financing in 2026. In the third quarter of
2026, Royalty Pharma collected interest of $6 million on its cash and cash
equivalents, which partially offset interest paid.
Royalty Pharma today provides this guidance based on its most up-to-date view of
its prospects. This guidance assumes no major unforeseen adverse events or
changes in foreign exchange rates and excludes the contributions from
transactions announced subsequent to the date of this press release.
Royalty Pharma Press Release| November 4, 2026 2
─────────────────────────────────────────────────────
Portfolio Receipts Highlights
Three Months
Ended
September
30,
($ in
millions; 2026 2025 Change
unaudited)
Products: Marketers: Therapeutic
Area:
Cystic Rare
fibrosis Vertex disease 225 222 1%
franchise
Trelegy GSK Respiratory 89 96 (6)%
Tremfya Johnson & Immunology 80 49 61%
Johnson
Evrysdi Roche Rare 71 52 38%
disease
Tysabri Biogen Neuroscien… 67 68 (1)%
Voranigo Servier Oncology 55 33 65%
Xtandi Pfizer, Oncology 51 50 3%
Astellas
AbbVie,
Imbruvica Johnson & Oncology 31 41 (24)%
Johnson
Exelixis,
Cabometyx/… Ipsen, Oncology 24 21 13%
Takeda
Imdelltra Amgen Oncology 19 — n/a
Trodelvy Gilead Oncology 16 12 30%
Spinraza Biogen Rare 14 14 0%
disease
Amvuttra Alnylam Rare 10 — n/a
disease
Promacta Novartis Hematology 9 38 (75)%
Other 121 114 6%
products(5)
Royalty 883 811 9%
Receipts
Milestones
and other 7 3 138%
contractual
receipts
Portfolio 890 814 9%
Receipts
Amounts shown in the table may not add due to rounding.
Royalty Receipts
was $883 million in the third quarter of 2026, an increase of 9% compared to
$811 million in the third quarter of 2025. The increase was primarily driven by
Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by declines from
Promacta due to U.S. generic competition and from Imbruvica. Royalty Receipts
from Evrysdi included the benefit of the additional royalties acquired in
December 2025.
Portfolio Receipts
was $890 million in the third quarter of 2026, an increase of 9% compared to
$814 million in the third quarter of 2025, primarily driven by the same Royalty
Receipts increases noted above, in addition to higher Milestones and other
contractual receipts.
Royalty Pharma Press Release| November 4, 2026 3
─────────────────────────────────────────────────────
Liquidity and Capital Resources
Royalty Pharma’s liquidity and capital resources are summarized below:
As of September 30, 2026, Royalty Pharma had cash and cash equivalents of $514
million and total debt with principal value of $8.8 billion. The reduction in
total debt from $9.2 billion as of June 30, 2026 reflects payment of the $380
million term loan in July 2026.
In the third quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235
per share, equating to $135 million in dividends and distributions.
Royalty Pharma repurchased approximately 1.5 million Class A ordinary shares for
$87 million in the third quarter and 3.5 million Class A ordinary shares for
$183 million during the first nine months of 2026. The weighted-average number
of diluted Class A ordinary shares outstanding for the third quarter of 2026 was
557 million as compared to 560 million for the third quarter of 2025.
Liquidity Summary
Three Months Ended September 30,
($ in millions; unaudited) 2026 2025
Portfolio Receipts 890 814
Payments for operating and
professional -50 -34
costs
Adjusted EBITDA (non-GAAP) 840 779
Interest paid, net -167 -123
Portfolio Cash Flow (non-GAAP) 673 657
Amounts may not add due to rounding.
•
Adjusted EBITDA (non-GAAP)
was $840 million in the third quarter of 2026. Payments for operating and
professional costs were 5.6% of Portfolio Receipts. Adjusted EBITDA is
calculated as Portfolio Receipts minus payments for operating and professional
costs.
•
Portfolio Cash Flow (non-GAAP)
was $673 million in the third quarter of 2026. Portfolio Cash Flow is calculated
as Adjusted EBITDA minus interest paid or received, net. This measure reflects
the cash generated by Royalty Pharma’s business that can be redeployed into
value-enhancing royalty acquisitions, used to repay debt, returned to
shareholders through dividends or share purchases, or utilized for other
discretionary investments.
Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to
the most directly comparable GAAP financial measure, net cash provided by
operating activities.
Capital Deployment reflects cash payments during the period for new and
previously announced transactions. Capital Deployment was $362 million in the
third quarter of 2026, consisting primarily of R&D funding for JNJ‑4804 and
upfront payments for cliramitug, Zoryve and Mimrylo (see 'Royalty
Transactions'). Capital Deployment was $1.2 billion for the nine months ended
September 30, 2026, with the announced value of transactions of $1.9 billion.
The table below details Capital Deployment by category:
Capital Deployment
Three Months Nine Months
Ended September Ended September
30, 30,
($ in millions; 2026 2025 2026 2025
unaudited)
Purchases of
available for — — — -75
sale debt
securities
Acquisitions of
financial -279 -962 -982 -964
royalty assets
Development-st…
funding -70 -51 -193 -402
payments
Milestone -13 — -63 -269
payments
Contributions
from legacy — -0 — 0
non-controlling
interests - R&D
Capital -362 -1,013 -1,239 -1,709
Deployment
Amounts may not add due to rounding.
Royalty Pharma Press Release| November 4, 2026 4
─────────────────────────────────────────────────────
Royalty Transactions
As of November 3, 2026, Royalty Pharma has announced new transactions of up to
$1.9 billion, which reflects the entire amount of potential capital committed
for new transactions, including potential future milestones. In the third
quarter of 2026, the following transactions were announced:
• In September 2026, Royalty Pharma acquired a royalty interest in Zoryve from
AstraZeneca for $100 million upfront. Zoryve, marketed by Arcutis
Biotherapeutics, is a topical phosphodiesterase type 4 (PDE4) inhibitor approved
for atopic dermatitis, seborrheic dermatitis and plaque psoriasis.
• In August 2026, Royalty Pharma acquired a royalty interest in Mimrylo,
formerly known as rusfertide, from Zealand Pharma for $100 million, consisting
of $50 million paid upfront and the remaining $50 million payable on the first
anniversary of the closing. Marketed by Takeda, Mimrylo is a first-in-class
therapy approved for polycythemia vera, a rare and chronic blood disorder.
• In July 2026, Royalty Pharma acquired a portion of Neurimmune AG’s royalty
interest in AstraZeneca’s cliramitug for up to $425 million, including $125
million upfront. Cliramitug is a Phase 3 first-in-class transthyretin
(TTR)-fibril-depleting antibody designed to remove amyloid deposits in patients
with TTR amyloidosis with cardiomyopathy, a progressive, degenerative and fatal
disease caused by misfolded proteins that accumulate in the heart.
The information in this section should be read together with Royalty Pharma’s
reports and documents filed with the SEC at www.sec.gov and the reader is also
encouraged to review all other press releases and information available in the
Investors section of Royalty Pharma’s website at www.royaltypharma.com .
Key Developments Relating to the Portfolio
The key developments related to Royalty Pharma’s royalty interests are discussed
below based on disclosures from the marketers of the products.
In October 2026, Novartis announced that the
regulatory submission for pelabresib in
pelabresib myelofibrosis was completed in the European
Union, based on the positive Phase 3 MANIFEST-2
study.
In October 2026, Revolution Medicines announced
that the European Medicines Agency’s Committee
for Medicinal Products for Human Use (CHMP) had
adopted a positive opinion of Rasonque for the
treatment of adult patients with metastatic
pancreatic adenocarcinoma who have received at
least one prior systemic therapy.
In October 2026, Royalty Pharma funded the
required first $250 million tranche of the up to
$750 million senior secured term loans to
Revolution Medicines. Additionally, Revolution
Medicines elected not to exercise its option for
Rasonque (daraxonrasib) the third royalty funding tranche (which was up
to $250 million). Up to an additional $500
million may be available at Revolution Medicines’
option under each of the senior secured term loan
and royalty funding agreement, based on the
achievement of certain milestones.
In August 2026, Revolution Medicines announced
that the U.S. Food and Drug Administration (FDA)
approved Rasonque for the treatment of adults
with metastatic pancreatic adenocarcinoma who
have received at least one prior systemic therapy
or who are not candidates for multiagent systemic
therapy.
In October 2026, Syndax Pharmaceuticals (Syndax)
announced that the Phase 2 MAXPIRe trial of
Niktimvo in idiopathic pulmonary fibrosis (IPF)
Niktimvo did not meet its primary endpoint. Syndax does
not plan to move forward with further development
in IPF. The results do not affect ongoing trials
of Niktimvo in other indications.
In October 2026, Teva Pharmaceuticals (Teva)
announced that the FDA approved Weltruza for
Weltruza (TEV-’749) extended-release injectable suspension, a new,
once-monthly, subcutaneous long-acting injectable
(LAI) for the treatment of schizophrenia in
adults.
In September 2026, Roche announced that Phase 3
trontinemab studies of trontinemab in early Alzheimer’s
disease have fully enrolled, with data expected
in the first half of 2028.
In September 2026, Amgen announced positive
results from the Phase 3 DeLLphi-305 study of
Imdelltra in combination with Imfinzi as
first-line maintenance treatment for
extensive-stage small cell lung cancer. The study
Imdelltra met its primary endpoint at a pre-specified
interim analysis, demonstrating a statistically
significant and clinically meaningful improvement
in overall survival, and also met secondary
endpoints of progression-free survival and
objective response rate.
Royalty Pharma Press Release| November 4, 2026 5
─────────────────────────────────────────────────────
In September 2026, Pharvaris
announced positive results from the
CHAPTER-3 pivotal Phase 3 study
evaluating deucrictibant
extended-release for the prevention
of hereditary angioedema (HAE)
attacks. The primary endpoint and
all secondary efficacy endpoints
were met with statistical
significance.
In July 2026, Pharvaris announced
that the FDA accepted its New Drug
Application (NDA) for deucrictibant
immediate-release for the on-demand
treatment of HAE attacks and
assigned a Prescription Drug User
Fee Act (PDUFA) date of April 23,
2027.
In September 2026, Novartis
announced that the Phase 3
Lp(a)HORIZON trial of pelacarsen did
not meet its primary endpoint of
reducing the risk of cardiovascular
events in the overall study
population compared to placebo. In
the third quarter of 2026, Royalty
Pharma recorded a non-cash
deucrictibant impairment charge of $150 million
pelacarsen related to pelacarsen.
──────────────────────────────────────────────────────────────────────────────
In September 2026, Teva announced
positive topline results from an
ongoing Phase 2a study of TEV-’408,
an anti-IL-15 antibody, in adults
with celiac disease. The study met
its primary endpoint, demonstrating
statistically significant and
clinically meaningful prevention of
TEV-’408 gluten-induced intestinal damage
versus placebo at week 8, and was
well tolerated, with no safety
signals observed to date.
In July 2026, Teva announced plans
to advance TEV-’408 into a Phase 2b
study in patients with non-segmental
vitiligo, following positive Phase
1b results.
In August 2026, Takeda announced
that the FDA approved Mimrylo, a
Mimrylo (rusfertide) hepcidin mimetic peptide, for the
treatment of erythrocytosis in
adults with polycythemia vera.
In August 2026, Jazz Pharmaceuticals
announced that the FDA approved
Ziihera in combination with
chemotherapy, with or without
Ziihera tislelizumab, for the first-line
treatment of adults with metastatic
human epidermal growth factor
receptor 2 (HER2)-positive
gastroesophageal adenocarcinoma.
In August 2026, Gilead announced
that the European Commission
approved Trodelvy in combination
Trodelvy with Keytruda as a first-line
treatment for PD-L1-positive
metastatic triple-negative breast
cancer.
In August 2026, Teva announced that
the FDA accepted its NDA for
ecopipam for the treatment of
ecopipam pediatric Tourette syndrome and
granted the application Priority
Review with a PDUFA date late in the
first quarter of 2027.
In August 2026, Zenas BioPharma
announced that the FDA accepted for
review its Biologics License
obexelimab Application for obexelimab for the
treatment of immunoglobulin
G4-related disease (IgG4-RD) and
assigned a PDUFA target action date
of May 27, 2027.
In July 2026, GSK announced that the
FDA approved Jideytro, a ROS
proto-oncogene 1 (ROS1)-selective
inhibitor, for the treatment of
adult patients with metastatic
ROS1-positive non-small cell lung
cancer who have received a prior
Jideytro (zidesamtinib) and ROS1 kinase inhibitor.
neladalkib In July 2026, GSK announced that it
completed the acquisition of
Nuvalent for approximately $10.6
billion, including Jideytro and
neladalkib, two highly selective
ROS1 and anaplastic lymphoma kinase
inhibitors for the treatment of
non-small cell lung cancer.
Financial Results Call
Royalty Pharma will host a conference call and simultaneous webcast to discuss
its third quarter of 2026 results today at 8:00 a.m. Eastern Time. Please visit
the “Investors” page of the company’s website at
https://www.royaltypharma.com/investors/events to obtain conference call
information and to view the live webcast. A replay of the conference call and
webcast will be archived on the company’s website for at least 30 days.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical
royalties and a leading funder of innovation across the biopharmaceutical
industry, collaborating with innovators from academic institutions, research
hospitals and non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has assembled a
portfolio of royalties which entitles it to payments based directly on the top-
line sales of many of the industry’s leading therapies. Royalty Pharma’s current
portfolio includes royalties on more than 35 commercial products, including
Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza,
Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya,
AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy,
Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 16 development-stage
product candidates.
Royalty Pharma Press Release| November 4, 2026 6
─────────────────────────────────────────────────────
Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain
all of the information you may desire. Statements contained herein are made as
of the date of this document unless stated otherwise, and neither the delivery
of this document at any time, nor any sale of securities, shall under any
circumstances create an implication that the information contained herein is
correct as of any time after such date or that information will be updated or
revised to reflect information that subsequently becomes available or changes
occurring after the date hereof.
This document contains statements that constitute “forward-looking statements”
as that term is defined in the United States Private Securities Litigation
Reform Act of 1995, including statements that express the company’s opinions,
expectations, beliefs, plans, objectives, assumptions or projections regarding
future events or future results, in contrast with statements that reflect
historical facts. Examples include discussion of Royalty Pharma’s strategies,
financing plans, growth opportunities, market growth and plans for capital
deployment, plus the benefits of the internalization transaction, including
expected accretion, enhanced alignment with shareholders, increased investment
returns, expectations regarding management continuity, transparency and
governance, and the benefits of simplification to its structure. In some cases,
you can identify such forward-looking statements by terminology such as
“anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,”
“expect,” “may,” “will,” “would,” “could” or “should,” the negative of these
terms or similar expressions. Forward-looking statements are based on
management’s current beliefs and assumptions and on information currently
available to the company. However, these forward-looking statements are not a
guarantee of Royalty Pharma’s performance, and you should not place undue
reliance on such statements. Forward-looking statements are subject to many
risks, uncertainties and other variable circumstances, and other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company’s control and could cause its actual results to
differ materially from those it thought would occur. The forward-looking
statements included in this document are made only as of the date hereof. The
company does not undertake, and specifically declines, any obligation to update
any such statements or to publicly announce the results of any revisions to any
such statements to reflect future events or developments, except as required by
law.
Certain information contained in this document relates to or is based on
studies, publications, surveys and other data obtained from third-party sources
and the company’s own internal estimates and research. While the company
believes these third-party sources to be reliable as of the date of this
document, it has not independently verified, and makes no representation as to
the adequacy, fairness, accuracy or completeness of, any information obtained
from third-party sources. In addition, all of the market data included in this
document involves a number of assumptions and limitations, and there can be no
guarantee as to the accuracy or reliability of such assumptions. Finally, while
the company believes its own internal research is reliable, such research has
not been verified by any independent source.
For further information, please reference Royalty Pharma’s reports and documents
filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR
on the SEC’s website at www.sec.gov.
Portfolio Receipts
Portfolio Receipts is a key performance metric that represents Royalty Pharma’s
ability to generate cash from Royalty Pharma’s portfolio investments, the
primary source of capital that is deployed to make new portfolio investments.
Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and
other contractual receipts. Royalty Receipts includes variable payments based on
sales of products, net of contractual payments to the legacy non-controlling
interests, that are attributed to Royalty Pharma.
Milestones and other contractual receipts include sales-based or regulatory
milestone payments and other fixed contractual receipts, net of contractual
payments to legacy non-controlling interests, that are attributed to Royalty
Pharma. Portfolio Receipts does not include royalty receipts and milestones and
other contractual receipts that were received on an accelerated basis under the
terms of the agreement governing the receipt or payment. Portfolio Receipts also
does not include proceeds from equity securities or proceeds from purchases and
sales of marketable securities, both of which are not central to Royalty
Pharma’s fundamental business strategy. 2025 Portfolio Receipts does not include
the $511 million of proceeds from the sale of the MorphoSys Development Funding
Bonds, as the transaction was treated as an asset sale.
Portfolio Receipts is calculated as the sum of the following line items from
Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash
collections from financial royalty assets, Cash collections from intangible
royalty assets, Other royalty cash collections, Proceeds from available for sale
debt securities a nd Distributions from equity method investees less
Distributions to legacy non-controlling interests - Portfolio Receipts , which
represent contractual distributions of Royalty Receipts, milestones and other
contractual receipts to the Legacy Investors Partnerships.
Royalty Pharma Press Release| November 4, 2026 7
─────────────────────────────────────────────────────
Use of Non-GAAP Measures
Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that
exclude the impact of certain items and therefore have not been calculated in
accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio
Cash Flow are important non-GAAP measures used to analyze liquidity because they
are key components of certain material covenants contained within Royalty
Pharma’s credit agreement. Royalty Pharma cautions readers that amounts
presented in accordance with the definitions of Adjusted EBITDA and Portfolio
Cash Flow may not be the same as similar measures used by other companies or
analysts. These non-GAAP liquidity measures have limitations as analytical
tools, and you should not consider them in isolation or as a substitute for the
analysis of Royalty Pharma’s results as reported under GAAP.
The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty
Pharma are the same as the definitions in the credit agreement. Noncompliance
with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio
covenants under the credit agreement could result in lenders requiring the
company to immediately repay all amounts borrowed. If Royalty Pharma cannot
satisfy these covenants, it would be prohibited under the credit agreement from
engaging in certain activities, such as incurring additional indebtedness,
paying dividends, making certain payments, and acquiring and disposing of
assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to
the assessment of Royalty Pharma’s liquidity.
Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity
measures in the evaluation of the company’s ability to generate cash from
operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when
considering available cash, including for decision-making purposes related to
funding of acquisitions, debt repayments, dividends and other discretionary
investments. Further, these non-GAAP liquidity measures help management, the
audit committee and investors evaluate the company’s ability to generate
liquidity from operating activities.
The company has provided reconciliations of these non-GAAP liquidity measures to
the most directly comparable GAAP financial measure, being net cash provided by
operating activities in Table 4.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
[email protected]
Royalty Pharma Press Release| November 4, 2026 8
─────────────────────────────────────────────────────
Royalty Pharma plc
Condensed Consolidated Statements of Operations
(7) (unaudited)
Table 1
Three Months Ended September 30,
($ in millions) 2026 2025
Income and other revenues
Income from financial royalty 648 579
assets
Other royalty income and 42 30
revenues
Total income and other revenues 690 609
Operating (income)/expense
Provision for changes in
expected cash -88 12
flows from financial royalty
assets
Provision for credit losses on
unfunded 4 1
commitments
Research and development funding 63 51
expense
General and administrative
expenses
(includes 105 and 73 of
share-based
compensation expense for the 150 119
three
months ended September 30, 2026
and
2025, respectively)
Financial royalty asset 150 —
impairment
Total operating expense, net 279 182
Operating income 411 427
Other (income)/expense
Equity in earnings of equity
method -9 -16
investees
Interest expense 90 80
Other expense/(income), net 63 -77
Total other expense/(income), 144 -13
net
Consolidated net income before 267 440
tax
Income tax expense — —
Consolidated net income 267 440
Net income attributable to 122 156
non-controlling interests
Net income attributable to
Royalty 145 284
Pharma plc
Amounts may not add due to rounding.
Royalty Pharma Press Release| November 4, 2026 9
─────────────────────────────────────────────────────
Royalty Pharma plc
Selected Balance Sheet Data (unaudited)
Table 2
As of September 30, As of December 31,
($ in millions) 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash equivalents 514 619
Total current and non-current
financial 17,079 17,063
royalty assets, net
Total assets 19,461 19,621
Current portion of long-term 997 380
debt
Long-term debt, net of current 7,591 8,571
portion
Total liabilities 9,666 9,906
Total shareholders’ equity 9,795 9,715
Royalty Pharma Press Release| November 4, 2026 10
──────────────────────────────────────────────────────
Royalty Pharma plc
Condensed Consolidated Statements of Cash Flows (unaudited)
Table 3
Three Months Nine Months
Ended September Ended September
30, 30,
($ in millions) 2026 2025 2026 2025
Cash flows from
operating
activities:
Cash
collections
from financial 930 882 2,660 2,439
royalty
assets
Cash
collections
from intangible 0 0 4 1
royalty
assets
Other royalty
cash 38 29 104 85
collections
Distributions
from equity 8 — 33 13
method
investees
Interest 6 7 18 28
received
Development-st…
funding -70 -51 -193 -402
payments
Payments for
operating and -50 -34 -123 -230
professional
costs
Payments for -3 -2 -18 -2
Employee EPAs
Interest paid -173 -130 -352 -270
Net cash
provided by 686 703 2,133 1,663
operating
activities
Cash flows from
investing
activities:
Acquisition of
businesses, net — -0 — -74
of cash
acquired
Distributions
from equity 1 1 30 100
method
investees
Purchases of
equity — — -28 -4
securities
Proceeds from
equity — — 36 —
securities
Purchases of
available for — — — -75
sale debt
securities
Proceeds from
available for 6 3 14 18
sale debt
securities
Proceeds from
sales of
available for — — — 511
sale debt
securities
Acquisitions of
financial -279 -962 -982 -964
royalty assets
Milestone -13 — -63 -269
payments
Other -0 — -1 -9
Net cash used
in investing -286 -958 -993 -766
activities
Cash flows from
financing
activities:
Distributions
to legacy
non-controlling -93 -102 -257 -276
interests -
Portfolio
Receipts
Distributions
to continuing -33 -34 -108 -127
non-controlling
interests
Dividends to -105 -95 -315 -284
shareholders
Repurchases of
Class A -86 -146 -181 -1,147
ordinary shares
Contributions
from legacy — -0 — 0
non-controlling
interests - R&D
Contributions
from
non-controlling — 0 — 6
interests -
other
Proceeds from
revolving 50 1,275 50 1,275
credit facility
Repayment of
revolving -50 -1,275 -50 -1,275
credit facility
Repayment of -380 -1,000 -380 -1,000
long-term debt
Proceeds from
issuance of
long-term — 1,954 — 1,954
debt, net of
discount
Debt issuance 0 -14 -2 -14
costs and other
Other -1 — -2 —
Net cash (used
in)/provided by -699 563 -1,245 -886
financing
activities
Net change in
cash and cash -298 307 -105 10
equivalents
Cash and cash
equivalents, 812 632 619 929
beginning of
period
Cash and cash
equivalents, 514 939 514 939
end of period
EPAs: Equity Performance Awards. Amounts may not add due to rounding.
Royalty Pharma Press Release| November 4, 2026 11
──────────────────────────────────────────────────────
Royalty Pharma plc
GAAP to Non-GAAP Reconciliation (unaudited)
Table 4
Three Months Ended September 30,
($ in millions) 2026 2025
Net cash provided by operating 686 703
activities (GAAP)
Adjustments:
Proceeds from available for sale
debt 6 3
securities(6)
Distributions from equity method 1 1
investees(6)
Interest paid, net(6) 167 123
Development-stage funding 70 51
payments
Distributions to legacy
non-controlling -93 -102
interests - Portfolio
Receipts(6)
Payments for Employee EPAs 3 2
Adjusted EBITDA (non-GAAP) 840 779
Interest paid, net(6) -167 -123
Portfolio Cash Flow (non-GAAP) 673 657
EPAs: Equity Performance Awards. Amounts may not add due to rounding.
Royalty Pharma Press Release| November 4, 2026 12
──────────────────────────────────────────────────────
Royalty Pharma plc
Description of Approved Indications for Select Portfolio Therapies
Table 5
Cystic fibrosis franchise Cystic fibrosis
Trelegy Chronic obstructive pulmonary disease and
asthma
Tremfya Plaque psoriasis, psoriatic arthritis,
ulcerative colitis and Crohn’s disease
Evrysdi Spinal muscular atrophy
Tysabri Relapsing forms of multiple sclerosis
Voranigo Low-grade glioma
Xtandi Prostate cancer
Imbruvica Hematological malignancies and chronic graft
versus host disease
Cabometyx/Cometriq Kidney, liver and thyroid cancer
Imdelltra Small cell lung cancer
Trodelvy Breast cancer
Spinraza Spinal muscular atrophy
Amvuttra Transthyretin amyloidosis
Promacta Chronic immune thrombocytopenia purpura and
aplastic anemia
Royalty Pharma Press Release| November 4, 2026 13
──────────────────────────────────────────────────────
Notes
(1) Portfolio Receipts is defined above in the section entitled “Portfolio
Receipts.”
(2) Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts
minus payments for operating and professional costs. Operating and professional
costs reflect Payments for operating and professional costs from the GAAP
condensed consolidated statements of cash flows. See GAAP to Non-GAAP
reconciliation in Table 4.
(3) Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA
minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in
Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s
business that can be redeployed into value-enhancing royalty acquisitions, used
to repay debt, returned to shareholders through dividends or share purchases or
utilized for other discretionary investments.
(4) Capital Deployment is calculated as the summation of the following line
items from Royalty Pharma’s GAAP condensed consolidated statements of cash
flows: Investments in equity method investees, Purchases of available for sale
debt securities, Acquisitions of financial royalty assets, Acquisitions of other
financial assets, Milestone payments and Development-stage funding payments less
Contributions from legacy non-controlling interests - R&D .
(5) Other products primarily include Royalty Receipts on the following products:
Crysvita, Erleada, Farxiga/Onglyza, IDHIFA, Niktimvo, Nurtec ODT, Orladeyo,
Prevymis, Skytrofa, Yorvipath and distributions from the Legacy SLP Interest,
which is presented as Distributions from equity method investees on the GAAP
condensed consolidated statements of cash flows.
(6) The table below shows the line item for each adjustment and the direct
location for such line item on the GAAP condensed consolidated statements of
cash flows.
Reconciling Adjustment Statements of Cash Flows
Classification
Interest paid, net Operating activities(Interest
paidlessInterest received)
Distributions from equity method Investing activities
investees
Proceeds from available for sale
debt Investing activities
securities
Distributions to legacy
non-controlling Financing activities
interests - Portfolio Receipts
(7) The condensed consolidated statement of operations for 2025 has been recast
to reflect the adoption of ASU 2025-07 by removing the gains previously
recognized on derivative.
Royalty Pharma Press Release| November 4, 2026 14
──────────────────────────────────────────────────────